🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 03674U300 (prev. 03674U201 )
- Market Cap
- Micro Cap · $1 Million
Business: Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
Notes: July 30 2018 -- Company filed form 15-12B with the SEC to terminate its reporting obligations. ________ May 1, 2017 -- Anthera Pharmaceuticals, Inc. (ANTH) will effect a one-for-eight (1-8) reverse split of its common stock. The CUSIP number will change to 03674U300.______________7/12/2013 -- 1-for-8 Reverse Split of Stock
Company Contact
- CEO
- Paul F. Truex
- CFO
- Christopher P. Lowe
- Headquarters
- 25801 Industrial Boulevard, Suite B, Hayward, CA 94545
- Phone
- 510-856-5600
- Fax
- 510-856-5597
- Investor Relations
- 510-856-5600 · info@anthera.com